PetIQ (PETQ) Stock Price, News & Analysis

Company Overview

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Key Stats

• Today's Range: $30.98 to $30.98
• 50-Day Range: $30.74 to $30.99
• 52-Week Range: $15.09 to $31.06
• Volume: N/A
• Average Volume: 480,624 shs
• Market Capitalization: $925.99 million
• P/E Ratio: 79.44
• Dividend Yield: N/A
• Price Target: $29.67
• Consensus Rating: Moderate Buy

PetIQ Stock Analysis - MarketRank™

PetIQ scored higher than 20% of companies evaluated by MarketBeat, and ranked 906th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PetIQ has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

PetIQ has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.50%

Earnings Growth

Earnings for PetIQ are expected to grow by 12.50% in the coming year, from $1.12 to $1.26 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PetIQ is 79.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.69.

Price to Earnings Ratio vs. Sector

The P/E ratio of PetIQ is 79.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.26.

Price to Book Value per Share Ratio

PetIQ has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PETQ.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PetIQ does not currently pay a dividend.

Dividend Growth

PetIQ does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for PETQ.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for PETQ on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PetIQ insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.62% of the stock of PetIQ is held by insiders.

Percentage Held by Institutions

94.99% of the stock of PetIQ is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PETQ Stock Analysis - Frequently Asked Questions

How were PetIQ's earnings last quarter?

PetIQ, Inc. (NASDAQ:PETQ) posted its earnings results on Wednesday, August, 7th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.20. The company's revenue was up 4.6% on a year-over-year basis.

When did PetIQ IPO?

PetIQ (PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PetIQ investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO), Voyager Therapeutics (VYGR) and TotalEnergies (TTE).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 2/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drugs, proprietaries, & sundries
• Sub-Industry: Wholesale
• Current Symbol: NASDAQ:PETQ
• CUSIP: N/A
• CIK: 1668673
• Web: www.petiq.com
• Phone: (208) 939-8900
• Fax: N/A
• Employees: 1,933
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.67
• High Stock Price Target: $31.00
• Low Stock Price Target: $28.00
• Potential Upside/Downside: -4.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.39
• Trailing P/E Ratio: 79.44
• Forward P/E Ratio: 27.66
• P/E Growth: N/A
• Net Income: $2.13 million
• Net Margins: 1.20%
• Pretax Margin: 1.29%
• Return on Equity: 18.75%
• Return on Assets: 5.15%

Debt

• Debt-to-Equity Ratio: 1.68
• Current Ratio: 2.58
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: $1.10 billion
• Price / Sales: 0.84
• Cash Flow: $2.68 per share
• Price / Cash Flow: 11.54
• Book Value: $7.58 per share
• Price / Book: 4.09

Miscellaneous

• Outstanding Shares: 29,890,000
• Free Float: 27,011,000
• Market Cap: $925.99 million
• Optionable: Optionable
• Beta: 1.73